Relation between cardiovascular diseases and cardiac hormones

心血管疾病与心脏激素的关系

基本信息

  • 批准号:
    17390233
  • 负责人:
  • 金额:
    $ 9.28万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2005
  • 资助国家:
    日本
  • 起止时间:
    2005 至 2006
  • 项目状态:
    已结题

项目摘要

The heart is a pump organ; however, it might produce many hormones in heart failure. Especially ANP and BNP are synthesized in large quantities. We have recently shown that various kinds of steroid hormone are also synthesized with a very small quantity. On the other hand, the action of steroid hormones in the heart may also exceed the conventional concept. In this study, we found that aldosterone has an action for anti-cellular dehydration; Na^+/H^+ exchanger 1 (NHE1) plays an important role there deeply. Cell shrinkage under high osmolarity was prevented by making Na^+ flow into the cell. However, when this became a long period, the rise of intracellular Ca^<2+> concentration leaded to cardiac hypertrophy.From the clinical side, we advanced researches on the medical treatment of heart failure. Although the inhibitory drugs of the renin-angiotensin system and anti-aldosterone agents are indispensable, too much rise of the potassium concentration is an important problem. We examined in detail what kind of factors would influence the potassium concentration by using 1,035 patients admitted to our institution. As a result, although renal insufficiency, diabetes, and use of the inhibitory drugs of the RAA system raised the potassium concentration, it was reduced rather in heart failure status. This is contrary to the conventional research findings; and thus the further argument is needed. On the other hand, although hANP is used more often in acute heart failure, there are still unknown mechanisms. In this study, we divided the heart failure patients into two groups; hANP treatment group and furosemide treatment group. Although the improvement of hemodynamic parameters were almost similar, the improvement of oxidative stress was significantly lager in the hANP group. This action will be confirmed also in the experiment using cultured neonatal rat cardiomyocyte, and the elucidation of that mechanism is a future subject.
心脏是一个泵器官;然而,它可能会产生许多导致心力衰竭的激素。尤其是ANP和BNP的合成量很大。我们最近发现,各种类固醇激素也可以以极少量的量合成。另一方面,类固醇激素在心脏中的作用也可能超出常规概念。在这项研究中,我们发现醛固酮具有抗细胞脱水的作用; Na^+/H^+ 交换器 1 (NHE1) 在那里发挥着重要作用。通过使 Na^+ 流入细胞来防止高渗透压下的细胞收缩。但时间长了,细胞内Ca^2+浓度升高,导致心脏肥大。从临床方面,我们对心力衰竭的药物治疗进行了深入的研究。虽然肾素-血管紧张素系统的抑制药物和抗醛固酮药物是不可缺少的,但钾浓度升高过多是一个重要问题。我们通过使用本机构收治的 1,035 名患者详细研究了哪些因素会影响钾浓度。结果,虽然肾功能不全、糖尿病和使用RAA系统抑制药物使钾浓度升高,但在心力衰竭状态下钾浓度反而降低。这与传统的研究结果相反;因此需要进一步论证。另一方面,虽然hANP更常用于急性心力衰竭,但仍存在未知的机制。在这项研究中,我们将心力衰竭患者分为两组; hANP治疗组和呋塞米治疗组。虽然血流动力学参数的改善几乎相似,但 hANP 组氧化应激的改善明显更大。该作用也将在使用培养的新生大鼠心肌细胞的实验中得到证实,并且该机制的阐明是未来的课题。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
ナトリウムとアルドステロンによる心筋肥大促進の機序
钠和醛固酮促进心肌肥厚的机制
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    吉村道博;他
  • 通讯作者:
心血管疾患とアルドステロン
心血管疾病和醛固酮
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    吉村道博;他
  • 通讯作者:
Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease
A predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure
A型利钠肽对心力衰竭患者治疗过程中减少氧化应激的主要作用
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Shono M;et al.
  • 通讯作者:
    et al.
Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium
在细胞外钠正常和升高的情况下醛固酮对心肌细胞的直接影响
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yamamuro M;et al.
  • 通讯作者:
    et al.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YOSHIMURA Michihiro其他文献

YOSHIMURA Michihiro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YOSHIMURA Michihiro', 18)}}的其他基金

Research for the mechanism of aldosterone synthesis in the adrenal gland and the heart.
研究肾上腺和心脏醛固酮合成机制。
  • 批准号:
    23591089
  • 财政年份:
    2011
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The pathophysiological role of aldosterone in cardiovascular disease.
醛固酮在心血管疾病中的病理生理学作用。
  • 批准号:
    20590841
  • 财政年份:
    2008
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study of Cardiac Steroidogenesis
心脏类固醇生成的研究
  • 批准号:
    15390249
  • 财政年份:
    2003
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Pathosignificance of cardiac aldosterone synthesis in heart failure
心脏醛固酮合成在心力衰竭中的病理意义
  • 批准号:
    13670729
  • 财政年份:
    2001
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular biological analysis of coronary spasm
冠状动脉痉挛的分子生物学分析
  • 批准号:
    11670694
  • 财政年份:
    1999
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetic analysis of endothelial nitric oxide synthase in patients with coronary spastic angina
冠状动脉痉挛性心绞痛患者内皮型一氧化氮合酶基因分析
  • 批准号:
    09670732
  • 财政年份:
    1997
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Expression of natriuretic peptides in heart failure
心力衰竭中利尿钠肽的表达
  • 批准号:
    07670795
  • 财政年份:
    1995
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

TOPMed WGS and Molecular Epidemiology Analyses for Cardiac Hypertrophy Phenotypes
心脏肥大表型的 TOPMed WGS 和分子流行病学分析
  • 批准号:
    10930193
  • 财政年份:
    2023
  • 资助金额:
    $ 9.28万
  • 项目类别:
Determining the role of Rac1 palmitoylation in cardiac hypertrophy and oxidative stress
确定 Rac1 棕榈酰化在心脏肥大和氧化应激中的作用
  • 批准号:
    10534386
  • 财政年份:
    2023
  • 资助金额:
    $ 9.28万
  • 项目类别:
Crosstalk Ca2+ Signaling between Ryanodine Receptors Type 1 and 2 in the Pathogenesis of Cardiac Hypertrophy and Heart Failure
心脏肥大和心力衰竭发病机制中 1 型和 2 型 Ryanodine 受体之间的串扰 Ca2 信号传导
  • 批准号:
    10660636
  • 财政年份:
    2023
  • 资助金额:
    $ 9.28万
  • 项目类别:
Role of eosinophil cationic proteins in cardiac hypertrophy
嗜酸性粒细胞阳离子蛋白在心脏肥大中的作用
  • 批准号:
    10735136
  • 财政年份:
    2023
  • 资助金额:
    $ 9.28万
  • 项目类别:
The studyon of p300 complex on cardiac hypertrophy and fibrosis during the development of heart failure
p300复合物对心力衰竭发生过程中心肌肥厚和纤维化的研究
  • 批准号:
    23K06098
  • 财政年份:
    2023
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Ultrasound-assisted microRNA delivery towards the treatment of pathological cardiac hypertrophy
超声辅助 microRNA 递送治疗病理性心脏肥大
  • 批准号:
    478248
  • 财政年份:
    2023
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Operating Grants
Non-canonical ERAD as a Regulator of Cardiac Hypertrophy
非典型 ERAD 作为心脏肥大的调节剂
  • 批准号:
    10544178
  • 财政年份:
    2022
  • 资助金额:
    $ 9.28万
  • 项目类别:
Molecular mechanisms driving maternal cardiac hypertrophy in pregnancy
妊娠期母体心脏肥大的分子机制
  • 批准号:
    486024
  • 财政年份:
    2022
  • 资助金额:
    $ 9.28万
  • 项目类别:
    Studentship Programs
Non-canonical ERAD as a Regulator of Cardiac Hypertrophy
非典型 ERAD 作为心脏肥大的调节剂
  • 批准号:
    10817347
  • 财政年份:
    2022
  • 资助金额:
    $ 9.28万
  • 项目类别:
Non-canonical ERAD as a Regulator of Cardiac Hypertrophy
非典型 ERAD 作为心脏肥大的调节剂
  • 批准号:
    10363838
  • 财政年份:
    2022
  • 资助金额:
    $ 9.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了